Molbio Diagnostics IPO: GMP 130, P/E 54.6, risks

What is trending about Molbio Diagnostics IPO

Molbio Diagnostics IPO is being heavily discussed on Reddit and other social feeds ahead of its opening. Most posts focus on grey market premium, valuation multiples, and business concentration risks. The issue is described as a mainboard, book-built IPO with a total size close to ₹940 crore. The price band is repeatedly shared as ₹768 to ₹807 per share. The subscription window is widely posted as August 10 to August 12, 2026. Many creators are also circulating the expected listing date of August 17, 2026. Alongside dates, the discussion has shifted to whether the valuation is justified versus recent profit growth. A recurring point is that the business mix is tilted towards government and aid agency demand.

Key dates, price band, and minimum bid details

Social posts list the IPO as opening on 10 August 2026 and closing on 12 August 2026. The tentative allotment date is shared as 13 August 2026 in multiple trackers. The listing is expected on both BSE and NSE, with a tentative date of 17 August 2026. The price band is consistent across sources at ₹768 to ₹807 per share. The lot size is repeatedly stated as 18 shares, with bids allowed in multiples of 18. Several posts calculate the minimum retail application amount as ₹14,526 at the upper band. The face value is mentioned as ₹1 per share. Some discussions also note a 1:10 sub-division and a 4:1 bonus issue in July 2025.

Issue size and structure that investors are sharing

The issue size is cited around ₹939.70 crore to ₹939.85 crore across social cards. Posts describe it as a 100% book-built offer. The fresh issue portion is stated as ₹200.00 crore. The offer for sale portion is stated around ₹739.70 crore. Some trackers also present the total shares figure as 1,16,46,246 shares aggregating to about ₹940 crore. The structure is framed as a mix of capital raise and shareholder exit, given the larger OFS component. People tracking anchor flows highlight an anchor investor bid date of Friday, August 7, 2026. The discussion generally treats the issue as a large, liquid mainboard listing rather than an SME IPO.

GMP chatter: why the premium numbers vary so much

Grey market premium is the most repeated number in social discussions, but it is not uniform. One widely circulated line pegs GMP at ₹130, updated frequently. Other trackers in the same conversation set show GMP around ₹122 with an estimated listing gain of about 15.12%. Another set of posts cites GMP at ₹180 with an estimated listing gain around 22.30% versus the upper band, and an estimated listing price near ₹987. Because these are crowd-sourced snapshots, posters keep emphasising that GMP changes frequently. The practical takeaway from the chatter is that sentiment has been positive, but not stable. Several comments also warn that GMP is not an official metric and can reverse quickly close to allotment.

Financial performance highlights that are being quoted

A large part of the debate is built on FY24 to FY26 growth shared in infographics. Revenue from operations is shown rising from ₹8,365.61 million in FY24 to ₹14,456.87 million in FY26. Another summary version expresses the same direction as total income rising from about ₹840 crore to ₹1,455 crore by FY26. PAT is shown rising from ₹835.42 million in FY24 to ₹1,641.40 million in FY26, described as nearly doubling. A separate line item often quoted is PAT increasing from ₹138.58 crore to ₹164.14 crore, alongside EBITDA at ₹328.24 crore. Posts also claim revenue increased by 42% and PAT rose by 18% between FY25 and FY26. Margins are discussed because PAT margin is shown moving between 11.28% and 13.48% in different year snapshots. This mix of growth and margin movement is central to the valuation debate.

A quick table of the numbers circulating online

The following table consolidates the most repeated FY24 to FY26 figures being shared in the social context. Units appear as posted, with some sources using ₹ crore summaries and others using ₹ million line items. The directional message in all shared cards is strong topline growth with higher absolute profits. At the same time, some shared metrics show margin variability year to year. Investors are using these numbers to cross-check the implied IPO valuation. They are also using them to compare FY26 profitability against the upper price band. The table below sticks strictly to figures present in the shared context.

Valuation lens: implied P/E around mid-50s

Valuation is framed around the IPO upper band of ₹807. One post calculates the P/E ratio at 54.63x using FY26 EPS of ₹14.77 and the upper price band. Another table cites pre-IPO P/E of 55.43x and post-IPO P/E of 56.67x, with EPS shown as ₹14.56 pre and ₹14.24 post. A separate comparison row lists diluted EPS of ₹14.77 and RoNW of 14.55%, with NAV per share of ₹101.51. The P/B is also quoted at 9.55 in one tracker card. Debt to equity is shown at 0.36 in the same set of metrics. The core debate in comments is not about whether the company is growing, but whether a mid-50s earnings multiple leaves enough margin of safety. Several users point out that listing-gain expectations from GMP can mask longer-term valuation risk.

Customer concentration: government and aid exposure is a key risk

The most specific risk being shared is customer concentration. A bullet-point note states that 84.56% of product revenue comes from governments and aid agencies. Users interpret this as high dependence on tenders and public health procurement cycles. The same note warns that policy shifts, tender losses, or funding cuts can hit sales hard. This is not presented as a hypothetical market risk, but as a direct revenue concentration fact in the shared material. Some commenters also connect this to the timing risk of large contracts and renewals. The overall tone is that strong institutional demand can support scale, but it can also create volatility when procurement priorities change. This point is frequently paired with product concentration, discussed next.

TB dependence: why the product mix matters to the story

Another repeated risk note is that tuberculosis drives a large portion of demand. The shared context states TB accounts for 70.20% of product revenue. It also states that 96.02% of kit units are TB-related. Commenters argue that such reliance increases sensitivity to changes in TB testing approach, screening intensity, or procurement budgets. Some posts explicitly say any shift in TB testing approach can pressure growth. Others read the same data as a sign of leadership in a focused category, but still acknowledge concentration. This TB dependence is often used as a counterweight to the growth narrative from FY24 to FY26. The net result in discussions is a more risk-aware approach, rather than a one-sided GMP-led view.

What retail investors are watching into the subscription window

Retail-focused posts concentrate on simple checkpoints for the three-day window. The first is the price band of ₹768 to ₹807 and the minimum lot size of 18 shares. The second is the minimum retail investment of ₹14,526 at the upper band, which is being used to plan applications. The third is the GMP range being quoted across sources, from about ₹122 to ₹180, with ₹130 also widely shared. The fourth is the valuation framing around P/E in the mid-50s, which influences whether investors aim for listing gains or longer holding periods. Finally, the two concentration metrics, 84.56% government and aid revenue and 70.20% TB revenue share, are being treated as the main fundamental risks. Based on the social context, most debate is about balancing near-term sentiment with these concentration and valuation constraints. The calendar, issue structure, and financial summaries are the core data points people are using before the book opens.